Click here for slides on this topic


IGT

Abbreviation for impaired glucose tolerance. IGT is a metabolic state between normoglycemia and diabetes defined by a plasma glucose level at the 2-hour point during a 75-g oral glucose tolerance test that is greater than or equal to 140 mg/dL but less than 200 mg/dL. See also Prediabetes.
The following content matched the glossary term: IGT

AACE 2015 guidelines Diabetes Diagnosis

Top

Summary of recommendations for screening and diagnosing type 2 diabetes from the 2015 AACE guidelines. 

ADA 2016 Type 2 Diabetes Prevention

Top

Recommendations for type 2 diabetes prevention or delay from the 2016 ADA guidelines

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 - High Serum Calcium Levels Increase Diabetes Risk

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

 

European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013

Top

NDEI's coverage of the European Association for the Study of Diabetes (EASD) 49th Annual Meeting 2013 from Barcelona, Spain

Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study

Top

Lorenzo C, Lee R, Haffner SM. Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study. Diabetes Care. 2012 Aug 24. Epub ahead of print. The Diabetes Prevention Program (DPP) reported no racial/ethnic differences in the incidence of diabetes in individuals with impaired glucose tolerance (IGT). Therefore, it has been hypothesized that factors associated with racial/ethnic disparities act prior to the development of IGT.

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 11, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 11, 2012

ORIGIN trial results, insulin and cancer, TINSAL-T2D results, and more.

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 10, 2012

Top

Daily coverage from the American Diabetes Association 72nd Scientific Sessions June 10, 2012

Beta-cell function preservation, ACCORD-BP, update on insulin therapies for diabetes treatment, pharmacology for diabetes prevention, and more. 

Clinical Insights in Diabetes Newsletter Archive

Top

Clinical Insights® in Diabetes Newsletter Archive

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: IGT Slides Found: 61
Hypertension and Glucose Tolerance in Four Ethnic Groups
Risk of Type 2 Diabetes in People With Impaired Glucose Tolerance
Type 2 Diabetes Prevention Studies
Effect of Orlistat on the Prevention of Type 2 Diabetes: XENDOS
Effect of Bariatric Surgery on Acute Insulin Response
Effect of Early Thiazolidinedione Therapy on A1C Levels
Effect of Early Thiazolidinedione Therapy on C-Peptide Levels
Effect of Early Thiazolidinedione Therapy on Diabetes Onset
IRAS: Number of CVD Risk Factors and Conversion to Type 2 Diabetes
GLP-1 Release Is Reduced in Type 2 Diabetes
Hypothetical Relationships Determine Categories of Glucose Tolerance
Finnish Diabetes Prevention Study: Sustained Benefit of Lifestyle Intervention
Decreased beta-Cell Function in Groups With Diabetes and at High Risk
Loss of beta-Cell Function in People Who Develop Type 2 Diabetes: Longitudinal Data
Changing Glucose: Different Rates at Different Clinical Stages
DECODE: IFG and IGT Are Associated With Increased Mortality Rate
IRAS: CVD Risk Factors Are Also Risk Factors for Type 2 Diabetes
Prevalence of IFG, IGT, and Prediabetes by Cardiometabolic Risk Factors
Prevalence of IFG, IGT, and Prediabetes According to a Combination of Central Obesity and Hyperinsulinemia
Indian Diabetes Prevention Programme-2: Study Design
Indian Diabetes Prevention Programme-2: Results
CANOE: Low-Dose Combination Therapy With Rosiglitazone Plus Metformin for Diabetes Prevention
CANOE: Development of New-Onset Diabetes With Low-Dose Combination Therapy Vs Placebo
DPP and DPPOS: Timeline
DPP: A Look Back
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN Omega-3 Fatty Acid Trial: Design
ORIGIN Omega-3 Fatty Acid Trial: Primary and Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Primary Outcome—CV Death
ORIGIN Omega-3 Fatty Acid Trial: Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
ORIGIN: Design
Long-term Weight Loss After Roux-en-Y Gastric Bypass
Long-term Change in BMI After Roux-en-Y Gastric Bypass
ORIGIN-GRACE: Design
ORIGIN-GRACE: Select Baseline Characteristics
ORIGIN-GRACE: Eligibility Criteria and Trial Profile
AACE 2015 Diabetes Guidelines Prediabetes Diagnosis IFG IGT PPT | NDEI
AACE 2015 Diabetes Guidelines Glucose Values Indicating Prediabetes PPT | NDEI
Blood Glucose Values Indicating Prediabetes or Type 2 Diabetes
Type 2 Diabetes Diagnostic Criteria US Preventive Guidelines | NDEI
Type 2 Diabetes Prevention ADA Guidelines 2016 | NDEI PPT
Cystic Fibrosis-Related Diabetes ADA Guidelines | NDEI PPT